-
1
-
-
77955635233
-
Cancer statistics, 2010
-
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
2
-
-
63049133092
-
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005
-
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1485-1491
-
-
Altekruse, S.F.1
McGlynn, K.A.2
Reichman, M.E.3
-
3
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
SHARP Investigators Study Group
-
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.F.6
-
4
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo- Controlled trial
-
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo- controlled trial. Lancet Oncol 2009;10:25-34.
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
Tsao, C.J.4
Qin, S.5
Kim, J.S.6
-
5
-
-
44449085884
-
Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma
-
Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 698-711
-
-
Llovet, J.M.1
Di Bisceglie, A.M.2
Bruix, J.3
Kramer, B.S.4
Lencioni, R.5
Zhu, A.X.6
-
6
-
-
79952231921
-
American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update
-
Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
-
(2011)
Hepatology
, vol.53
, pp. 1020-1022
-
-
Bruix, J.1
Sherman, M.2
-
7
-
-
41649102043
-
The cancer biomarker problem
-
DOI 10.1038/nature06913, PII NATURE06913
-
Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-52. (Pubitemid 351483368)
-
(2008)
Nature
, vol.452
, Issue.7187
, pp. 548-552
-
-
Sawyers, C.L.1
-
8
-
-
0033071014
-
Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein
-
Okuda K, Tanaka M, Kanazawa N, Nagashima J, Satomura S, Kinoshita H, et al. Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein. Int J Oncol 1999;14:256-71.
-
(1999)
Int J Oncol
, vol.14
, pp. 256-271
-
-
Okuda, K.1
Tanaka, M.2
Kanazawa, N.3
Nagashima, J.4
Satomura, S.5
Kinoshita, H.6
-
9
-
-
73349142702
-
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: Oncologic marker of radiologic response, progression, and survival
-
Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009;27:5734-42.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5734-5742
-
-
Riaz, A.1
Ryu, R.K.2
Kulik, L.M.3
Mulcahy, M.F.4
Lewandowski, R.J.5
Minocha, J.6
-
10
-
-
78649296731
-
Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma
-
Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci 2010;55:3576-83.
-
(2010)
Dig Dis Sci
, vol.55
, pp. 3576-3583
-
-
Tamura, Y.1
Igarashi, M.2
Kawai, H.3
Suda, T.4
Satomura, S.5
Aoyagi, Y.6
-
11
-
-
77957552077
-
New strategies in hepatocellular carcinoma: Genomic prognostic markers
-
Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, et al. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010;16:4688-94.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4688-4694
-
-
Villanueva, A.1
Hoshida, Y.2
Toffanin, S.3
Lachenmayer, A.4
Alsinet, C.5
Savic, R.6
-
12
-
-
75549088882
-
EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma
-
Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010;52:280-1.
-
(2010)
J Hepatol
, vol.52
, pp. 280-281
-
-
Terris, B.1
Cavard, C.2
Perret, C.3
-
13
-
-
40449099255
-
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma
-
DOI 10.1158/0008-5472.CAN-07-6013
-
Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-61. (Pubitemid 351346853)
-
(2008)
Cancer Research
, vol.68
, Issue.5
, pp. 1451-1461
-
-
Yamashita, T.1
Forgues, M.2
Wang, W.3
Jin, W.K.4
Ye, Q.5
Jia, H.6
Budhu, A.7
Zanetti, K.A.8
Chen, Y.9
Qin, L.-X.10
Tang, Z.-Y.11
Xin, W.W.12
-
14
-
-
60449087921
-
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features
-
Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012-24.
-
(2009)
Gastroenterology
, vol.136
, pp. 1012-1024
-
-
Yamashita, T.1
Ji, J.2
Budhu, A.3
Forgues, M.4
Yang, W.5
Wang, H.Y.6
-
15
-
-
70349871321
-
MicroRNA expression, survival, and response to interferon in liver cancer
-
Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437-47.
-
(2009)
N Engl J Med
, vol.361
, pp. 1437-1447
-
-
Ji, J.1
Shi, J.2
Budhu, A.3
Yu, Z.4
Forgues, M.5
Roessler, S.6
-
16
-
-
57349090407
-
Gene expression in fixed tissues and outcome in hepatocellular carcinoma
-
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
-
(2008)
N Engl J Med
, vol.359
, pp. 1995-2004
-
-
Hoshida, Y.1
Villanueva, A.2
Kobayashi, M.3
Peix, J.4
Chiang, D.Y.5
Camargo, A.6
-
17
-
-
77349092851
-
Molecular classification and novel targets in hepatocellular carcinoma: Recent advancements
-
Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51.
-
(2010)
Semin Liver Dis
, vol.30
, pp. 35-51
-
-
Hoshida, Y.1
Toffanin, S.2
Lachenmayer, A.3
Villanueva, A.4
Minguez, B.5
Llovet, J.M.6
-
18
-
-
54449083925
-
Molecular targeted therapies in hepatocellular carcinoma
-
Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
-
(2008)
Hepatology
, vol.48
, pp. 1312-1327
-
-
Llovet, J.M.1
Bruix, J.2
-
19
-
-
84859212951
-
Hepatocellular carcinoma
-
in press. DOI:10.1016/S0140-6736(11)61347-0
-
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012, in press. DOI:10.1016/S0140-6736(11)61347-0.
-
(2012)
Lancet
-
-
Forner, A.1
Llovet, J.M.2
Bruix, J.3
-
20
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
DOI 10.1158/0008-5472.CAN-04-1443
-
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. (Pubitemid 39331023)
-
(2004)
Cancer Research
, vol.64
, Issue.19
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
Wilkie, D.4
McNabola, A.5
Rong, H.6
Chen, C.7
Zhang, X.8
Vincent, P.9
McHugh, M.10
Cao, Y.11
Shujath, J.12
Gawlak, S.13
Eveleigh, D.14
Rowley, B.15
Liu, L.16
Adnane, L.17
Lynch, M.18
Auclair, D.19
Taylor, I.20
Gedrich, R.21
Voznesensky, A.22
Riedl, B.23
Post, L.E.24
Bollag, G.25
Trail, P.A.26
more..
-
21
-
-
55749088393
-
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
-
Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 3129-3140
-
-
Wilhelm, S.M.1
Adnane, L.2
Newell, P.3
Villanueva, A.4
Llovet, J.M.5
Lynch, M.6
-
22
-
-
0038374813
-
Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma
-
DOI 10.1053/jhep.2003.50204
-
Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003;37:1105-13. (Pubitemid 36538687)
-
(2003)
Hepatology
, vol.37
, Issue.5
, pp. 1105-1113
-
-
Mitsuhashi, N.1
Shimizu, H.2
Ohtsuka, M.3
Wakabayashi, Y.4
Ito, H.5
Kimura, F.6
Yoshidome, H.7
Kato, A.8
Nukui, Y.9
Miyazaki, M.10
-
23
-
-
0031690845
-
Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma
-
DOI 10.1016/S0046-8177(98)90205-2
-
Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998;29:986-91. (Pubitemid 28422048)
-
(1998)
Human Pathology
, vol.29
, Issue.9
, pp. 986-991
-
-
Torimura, T.1
Sata, M.2
Ueno, T.3
Kin, M.4
Tsuji, R.5
Suzaku, K.6
Hashimoto, O.7
Sugawara, H.8
Tanikawa, K.9
-
24
-
-
59149098933
-
Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy
-
Mizuguchi T, Nagayama M, Meguro M, Shibata T, Kaji S, Nobuoka T, et al. Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg 2009;13:325-33.
-
(2009)
J Gastrointest Surg
, vol.13
, pp. 325-333
-
-
Mizuguchi, T.1
Nagayama, M.2
Meguro, M.3
Shibata, T.4
Kaji, S.5
Nobuoka, T.6
-
25
-
-
47649102055
-
Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma
-
DOI 10.1111/j.1440-1746.2007.05175.x
-
Kuboki S, Shimizu H, Mitsuhashi N, Kusashio K, Kimura F, Yoshidome H, et al. Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:e157-64. (Pubitemid 352019432)
-
(2008)
Journal of Gastroenterology and Hepatology
, vol.23
, Issue.7 PART2
-
-
Kuboki, S.1
Shimizu, H.2
Mitsuhashi, N.3
Kusashio, K.4
Kimura, F.5
Yoshidome, H.6
Ohtsuka, M.7
Kato, A.8
Yoshitomi, H.9
Miyazaki, M.10
-
26
-
-
0020396015
-
Toxicology and response criteria of the Eastern Cooperative Oncology Group
-
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
-
(1982)
American Journal of Clinical Oncology: Cancer Clinical Trials
, vol.5
, Issue.6
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Davis, T.E.3
-
27
-
-
11344265442
-
Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma
-
DOI 10.1007/s00535-004-1469-8
-
Vejchapipat P, Tangkijvanich P, Theamboonlers A, Chongsrisawat V, Chittmittrapap S, Poovorawan Y. Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol 2004;39:1182-8. (Pubitemid 40074285)
-
(2004)
Journal of Gastroenterology
, vol.39
, Issue.12
, pp. 1182-1188
-
-
Vejchapipat, P.1
Tangkijvanich, P.2
Theamboonlers, A.3
Chongsrisawat, V.4
Chittmittrapap, S.5
Poovorawan, Y.6
-
28
-
-
84984586846
-
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma
-
Omata M, Lesmana LA, Tateishi R, Chen PJ, Lim SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74.
-
(2010)
Hepatol Int
, vol.4
, pp. 439-474
-
-
Omata, M.1
Lesmana, L.A.2
Tateishi, R.3
Chen, P.J.4
Lim, S.M.5
Yoshida, H.6
-
29
-
-
71249126197
-
Asian Oncology Summit. Management of hepatocellular carcinoma in Asia: Consensus statement from the Asian Oncology Summit 2009
-
Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, et al Asian Oncology Summit. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:1111-8.
-
(2009)
Lancet Oncol
, vol.10
, pp. 1111-1118
-
-
Poon, D.1
Anderson, B.O.2
Chen, L.T.3
Tanaka, K.4
Lau, W.Y.5
Van Cutsem, E.6
-
30
-
-
67649992397
-
NCCN clinical practice guidelines in oncology: Hepatobiliary cancers
-
Benson AB III, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009;7:350-91.
-
(2009)
J Natl Compr Canc Netw
, vol.7
, pp. 350-391
-
-
Benson III, A.B.1
Abrams, T.A.2
Ben-Josef, E.3
Bloomston, P.M.4
Botha, J.F.5
Clary, B.M.6
-
31
-
-
0038118504
-
Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma?
-
DOI 10.1097/01.MP.0000071841.17900.69
-
Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003;16:552-7. (Pubitemid 36718436)
-
(2003)
Modern Pathology
, vol.16
, Issue.6
, pp. 552-557
-
-
Moon, W.S.1
Rhyu, K.H.2
Kang, M.J.3
Lee, D.G.4
Yu, H.C.5
Yeum, J.H.6
Koh, G.Y.7
Tarnawski, A.S.8
-
32
-
-
65549105393
-
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: Systematic review and meta-analysis
-
Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009;100:1385-92.
-
(2009)
Br J Cancer
, vol.100
, pp. 1385-1392
-
-
Schoenleber, S.J.1
Kurtz, D.M.2
Talwalkar, J.A.3
Roberts, L.R.4
Gores, G.J.5
-
33
-
-
70350507211
-
Vascular endothelial growth factor in the management of hepatocellular carcinoma: A review of literature
-
Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009;115:4895-906.
-
(2009)
Cancer
, vol.115
, pp. 4895-4906
-
-
Kaseb, A.O.1
Hanbali, A.2
Cotant, M.3
Hassan, M.M.4
Wollner, I.5
Philip, P.A.6
-
34
-
-
80053974116
-
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma
-
Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011;29:3892-9.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3892-3899
-
-
Kaseb, A.O.1
Morris, J.S.2
Hassan, M.M.3
Siddiqui, A.M.4
Lin, E.5
Xiao, L.6
-
35
-
-
77957570088
-
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III treatment approaches in renal cancer global evaluation trial
-
Pena C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 2010;16:4853-63.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4853-4863
-
-
Pena, C.1
Lathia, C.2
Shan, M.3
Escudier, B.4
Bukowski, R.M.5
-
36
-
-
70149087258
-
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
-
Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009;20:616-24.
-
(2009)
Anticancer Drugs
, vol.20
, pp. 616-624
-
-
Bianchi, G.1
Loibl, S.2
Zamagni, C.3
Salvagni, S.4
Raab, G.5
Siena, S.6
-
37
-
-
67649946279
-
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study
-
Zhu AX, Dahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27:3027-35.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3027-3035
-
-
Zhu, A.X.1
Dahani, D.V.2
Duda, D.G.3
Di Tomaso, E.4
Ancukiewicz, M.5
Catalano, O.A.6
-
38
-
-
79960590467
-
Mechanism-related circulating proteins as biomarkers for clinical outcomes in patients with unresectable hepatocellular carcinoma receiving sunitinib
-
Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, et al. Mechanism-related circulating proteins as biomarkers for clinical outcomes in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med 2011;9:120.
-
(2011)
J Transl Med
, vol.9
, pp. 120
-
-
Harmon, C.S.1
DePrimo, S.E.2
Raymond, E.3
Cheng, A.L.4
Boucher, E.5
Douillard, J.Y.6
-
39
-
-
34547779489
-
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins
-
DePrimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.
-
(2007)
J Transl Med
, vol.5
, pp. 32
-
-
DePrimo, S.E.1
Bello, C.L.2
Smeraglia, J.3
Baum, C.M.4
Spinella, D.5
Rini, B.I.6
-
40
-
-
30944452436
-
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]
-
DOI 10.1200/JCO.2005.02.5635
-
Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-9. (Pubitemid 46657433)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.31
, pp. 8136-8139
-
-
Willett, C.G.1
Boucher, Y.2
Duda, D.G.3
Di, T.E.4
Munn, L.L.5
Tong, R.T.6
Kozin, S.V.7
Petit, L.8
Jain, R.K.9
Chung, D.C.10
Sahani, D.V.11
Kalva, S.P.12
Cohen, K.S.13
Scadden, D.T.14
Fischman, A.J.15
Clark, J.W.16
Ryan, D.P.17
Zhu, A.X.18
Blaszkowsky, L.S.19
Shellito, P.C.20
Mino-Kenudson, M.21
Lauwers, G.Y.22
more..
-
41
-
-
20944441692
-
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
-
DOI 10.1093/annonc/mdi118
-
Drevs J, Zirrgiebel U, Schmidt-Gersbach CIM, Mross K, Medinger M, Lee L, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005;16:558-65. (Pubitemid 40613321)
-
(2005)
Annals of Oncology
, vol.16
, Issue.4
, pp. 558-565
-
-
Drevs, J.1
Zirrgiebel, U.2
Schmidt-Gersbach, C.I.M.3
Mross, K.4
Medinger, M.5
Lee, L.6
Pinheiro, J.7
Wood, J.8
Thomas, A.L.9
Unger, C.10
Henry, A.11
Steward, W.P.12
Laurent, D.13
Lebwohl, D.14
Dugan, M.15
Marme, D.16
-
42
-
-
62349110279
-
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: Impact on angiogenic markers
-
Baar J, Silverman S, Lyons J, Fu P, Abdul-Karim F, Ziats N, et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic markers. Clin Cancer Res 2009;15:3583-90.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3583-3590
-
-
Baar, J.1
Silverman, S.2
Lyons, J.3
Fu, P.4
Abdul-Karim, F.5
Ziats, N.6
-
43
-
-
46449091500
-
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocelllular carcinoma
-
Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocelllular carcinoma. J Clin Oncol 2008;36:2992-8.
-
(2008)
J Clin Oncol
, vol.36
, pp. 2992-2998
-
-
Siegel, A.B.1
Cohen, E.I.2
Ocean, A.3
Lehrer, D.4
Goldenberg, A.5
Knox, J.J.6
-
44
-
-
79954451405
-
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
-
Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011;104:1262-9.
-
(2011)
Br J Cancer
, vol.104
, pp. 1262-1269
-
-
Loupakis, F.1
Cremolini, C.2
Fioravanti, A.3
Orlandi, P.4
Salvatore, L.5
Masi, G.6
-
45
-
-
36749052895
-
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
-
DOI 10.1073/pnas.0708148104
-
Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007;104:17069-74. (Pubitemid 350210993)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.43
, pp. 17069-17074
-
-
Ebos, J.M.L.1
Lee, C.R.2
Christensen, J.G.3
Mutsaers, A.J.4
Kerbel, R.S.5
-
47
-
-
34249297624
-
1 integrin-mediated pathway
-
DOI 10.1158/0008-5472.CAN-06-4100
-
Imanishi Y, Hu B, Jarzynka MJ, Guo P, Elishaev E, Bar-Joseph I, et al. Angiopoietin-2 stimulates breast cancer metastasis through the a5b1 integrin-mediated pathway. Cancer Res 2007;67:4254-63. (Pubitemid 46815072)
-
(2007)
Cancer Research
, vol.67
, Issue.9
, pp. 4254-4263
-
-
Imanishi, Y.1
Hu, B.2
Jarzynka, M.J.3
Guo, P.4
Elishaev, E.5
Bar-Joseph, I.6
Cheng, S.-Y.7
-
48
-
-
34447525629
-
Serum angiopoietin-2 as a clinical marker for lung cancer
-
Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007;132:200-6.
-
(2007)
Chest
, vol.132
, pp. 200-206
-
-
Park, J.H.1
Park, K.J.2
Kim, Y.S.3
Sheen, S.S.4
Lee, K.S.5
Lee, H.N.6
-
49
-
-
0032939205
-
Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma
-
Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341-5. (Pubitemid 29069983)
-
(1999)
Journal of Clinical Investigation
, vol.103
, Issue.3
, pp. 341-345
-
-
Tanaka, S.1
Mori, M.2
Sakamoto, Y.3
Makuuchi, M.4
Sugimachi, K.5
Wands, J.R.6
-
50
-
-
84857102544
-
-
South San Francisco, CA: Genentech USA, Inc. [updated 2010 Oct; cited 2011 Nov 28]. Available from
-
Herceptin (trastuzumab) prescribing information. South San Francisco, CA: Genentech USA, Inc. [updated 2010 Oct; cited 2011 Nov 28]. Available from: http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf.
-
Herceptin (Trastuzumab) Prescribing Information
-
-
-
52
-
-
74049152132
-
-
Thousand Oaks, CA: Amgen Inc. [updated 2011 Jun; cited 2011 Nov 28]. Available from
-
Vectibix (panitumumab) prescribing information. Thousand Oaks, CA: Amgen Inc. [updated 2011 Jun; cited 2011 Nov 28]. Available from: http://pi.amgen.com/ united-states/vectibix/vectibix-pi.pdf.
-
Vectibix (Panitumumab) Prescribing Information
-
-
-
53
-
-
84859815479
-
-
South San Francisco, CA: Genentech USA, Inc. [updated 2011 Aug; cited 2011 Nov 28]. Available from
-
Zelboraf (vemurafenib) prescribing information. South San Francisco, CA: Genentech USA, Inc. [updated 2011 Aug; cited 2011 Nov 28]. Available from: http://www.gene.com/gene/products/information/zelboraf/pdf/pi.pdf.
-
Zelboraf (Vemurafenib) Prescribing Information
-
-
-
54
-
-
84859837695
-
-
Philadelphia, PA: Pfizer Inc. [updated 2011 Oct; cited 2011 Nov 28]. Available from
-
Xalkori (crizotinib) prescribing information. Philadelphia, PA: Pfizer Inc. [updated 2011 Oct; cited 2011 Nov 28]. Available from: http://labeling. pfizer.com/showlabeling.aspx?id=676.
-
Xalkori (Crizotinib) Prescribing Information
-
-
-
55
-
-
33745220780
-
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype
-
Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-95.
-
(2006)
J Clin Invest
, vol.116
, pp. 1582-1595
-
-
Kaposi-Novak, P.1
Lee, J.S.2
Gomez-Quiroz, L.3
Coulouarn, C.4
Factor, V.M.5
Thorgeirsson, S.S.6
-
56
-
-
33846212284
-
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
-
DOI 10.1158/0008-5472.CAN-06-1377
-
Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8. (Pubitemid 46094197)
-
(2006)
Cancer Research
, vol.66
, Issue.24
, pp. 11851-11858
-
-
Liu, L.1
Cao, Y.2
Chen, C.3
Zhang, X.4
McNabola, A.5
Wilkie, D.6
Wilhelm, S.7
Lynch, M.8
Carter, C.9
-
57
-
-
77956654766
-
Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma
-
Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, et al. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin Cancer Res 2010;16:4616-24.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4616-4624
-
-
Kasahara, K.1
Arao, T.2
Sakai, K.3
Matsumoto, K.4
Sakai, A.5
Kimura, H.6
|